Search company, investor...

Founded Year

2016

Stage

Acquired | Acquired

Total Raised

$2.005B

Valuation

$0000 

About GRAIL

GRAIL develops technologies for early cancer detection. Its product includes Galleri which provides multi-cancer early detection tests. GRAIL was formerly known as PSC15. The company was founded in 2016 and is based in Menlo Park, California. In August 2021, GRAIL was acquired by Illumina.

Headquarters Location

1525 O'Brien Drive

Menlo Park, California, 94025,

United States

833-694-2553

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Expert Collections containing GRAIL

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GRAIL is included in 4 Expert Collections, including Digital Health 150.

D

Digital Health 150

300 items

The most promising digital health startups transforming the healthcare industry

D

Digital Health

10,553 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

P

Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.

O

Oncology Tech

457 items

This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.

GRAIL Patents

GRAIL has filed 134 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/30/2018

8/15/2023

Molecular biology, Genetics, Bioinformatics, DNA, Genomics

Grant

Application Date

11/30/2018

Grant Date

8/15/2023

Title

Related Topics

Molecular biology, Genetics, Bioinformatics, DNA, Genomics

Status

Grant

Latest GRAIL News

Grail partnership latest step for broader access to multicancer tests

Aug 26, 2023

Grail partnership latest step for broader access to multicancer tests Study to evaluate community outreach strategies for increasing early cancer screening in diverse populations, follows similar deal by Exact Sciences in June By Karen Tkach Tuzman, Director of Biopharma Intelligence August 25, 2023 7:09 PM UTC With real-world data becoming key for understanding the clinical utility of multicancer early detection (MCED) tests, evaluating the blood tests in diverse populations and care settings is critical. Non-profit partnerships announced this half by Grail and Exact Sciences aim to build that understanding by bringing the companies’ tests to underserved populations. In the absence of FDA approval and widespread reimbursement, real-world use of the cell-free DNA (cfDNA)-based Galleri MCED test from the Grail LLC unit of Illumina Inc. (NASDAQ:ILMN), which is marketed via the laboratory-developed test (LDT) pathway, is primarily limited to those who can afford the $949 price tag. ... BCIQ Company Profiles

GRAIL Frequently Asked Questions (FAQ)

  • When was GRAIL founded?

    GRAIL was founded in 2016.

  • Where is GRAIL's headquarters?

    GRAIL's headquarters is located at 1525 O'Brien Drive, Menlo Park.

  • What is GRAIL's latest funding round?

    GRAIL's latest funding round is Acquired.

  • How much did GRAIL raise?

    GRAIL raised a total of $2.005B.

  • Who are the investors of GRAIL?

    Investors of GRAIL include Illumina, ARCH Venture Partners, Public Sector Pension Investment Board, CPP Investments, Qiming Venture Partners and 28 more.

  • Who are GRAIL's competitors?

    Competitors of GRAIL include Owlstone Medical, Beacon Biomedical, Huna, ErleaDx, Freenome and 16 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare GRAIL to Competitors

Freenome Logo
Freenome

Freenome uses computational biology and machine learning techniques to detect cancer in its early and treatable stages. It detects cancer at an early stage through a routine blood draw and uses a proprietary algorithm method for systematized early detection. It was founded in 2014 and is based in South San Francisco, California.

20/20 GeneSystems Logo
20/20 GeneSystems

20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.

Owlstone Medical Logo
Owlstone Medical

Owlstone Medical is a diagnostics company developing a breathalyzer for disease detection. It offers a breath biopsy platform to enable early detection across multiple cancers and other related conditions. The company was founded in 2004 and is based in Cambridge, U.K.

L
Liquid Genomics

Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.

A
Accuragen

Accuragen has developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in minuscule concentrations of circulating cell-free DNA (cfDNA) in blood. The Company's technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining proprietary techniques in molecular biology and computational algorithm for error suppression. With Accuragen's technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.

OncoTAB Logo
OncoTAB

OncoTAB's technology was used to develop a blood test, Agkura Personal Score, which aids breast cancer detection in women with dense breast tissue.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.